Cargando…
Ranibizumab in retinopathy of prematurity – one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study
PURPOSE: The primary endpoint results from the comparing alternative ranibizumab dosages for safety and effcacy in retinopathy of prematurity (CARE-ROP) core study identified ranibizumab as an effective treatment to control acute retinopathy of prematurity (ROP). This study reports the 1- and 2-year...
Autores principales: | Stahl, Andreas, Bründer, Marie-Christine, Lagrèze, Wolf A., Molnár, Fanni E., Barth, Teresa, Eter, Nicole, Guthoff, Rainer, Krohne, Tim U., Pfeil, Johanna M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460412/ https://www.ncbi.nlm.nih.gov/pubmed/33742551 http://dx.doi.org/10.1111/aos.14852 |
Ejemplares similares
-
Neurodevelopmental Outcome of Infants with Gastroschisis at One-Year Follow-Up
por: Gupta, Vishal, et al.
Publicado: (2015) -
Frequency of retinopathy of prematurity (ROP) in infants screened for ROP: two years follow-up results of a single center in Turkey
por: Ugurlu, Adem
Publicado: (2021) -
Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
por: Nemoto, Rei, et al.
Publicado: (2012) -
Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova, Nadezhda P, et al.
Publicado: (2016) -
Neurodevelopmental Outcomes after Congenital Heart Disease Surgery in Infancy: A 2-Year Serial Follow-Up
por: Song, Kyeong Joo, et al.
Publicado: (2021)